BPIQ Blog

Summary: Biogen and Eisai's asset Lecanemab has a PDUFA date set for Friday 1/6/23 Lecanemab targets and effectively reduces beta-amyloid...

AUPH PR on settlement of patent disputes with the Indian generic company, Sun is very brief. See entire substantive portion of press...

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Last week we saw the TGTX get approval and the stock is up 50%. As we set our sights on January there's lot to be on the lookout for. We...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

TGTX BRIUMVI (Ublituximab) approved for MS on 12/28/2022! See the new label: https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/76...

Let's review moves from smid-cap biopharma companies during this past week. See Table 1 for weekly moves and moves YTD for companies and...

Last week we saw the MDGL NASH data on Monday and it's up over +300%. This next week we see LOTS of PDUFA events happening to close out...

Last week we saw the MDGL NASH data on Monday and it's up over +300%. This next week we see LOTS of PDUFA events happening to close out...

Summary: Esperion CLEAR outcomes data came out Dec 7 This was a month early and stock did not react well (down 15% on 12/7 and 32% that...